TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05715294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Application
Description: A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
Study: NCT05315193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured In-patient and Home plan
Description: A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Therapy
Description: In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)
Study: NCT05737810

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05956301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy will be administered through Nasal catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: High Flow Nasal Cannula will be administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic jet oxygenation and ventilation
Description: Nasal jet tube will be administered
Study: NCT05234684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib + R-CHOP
Description: The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + R-CHOP
Description: The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
Study: NCT02004782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
Study: NCT06387901

Intervention type: DRUG
Intervention: Paclitaxel Chemotherapy
Description: Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
Study: NCT05131100

Intervention type: DRUG
Intervention: Somavert
Description: As provided in real world practice
Study: NCT06077227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality therapy
Description: 6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: matched control group
Description: taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
Study: NCT06073574

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: MRI Scans as specified in the corresponding arm group.
Study: NCT05471661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent-specific T cells (penta-STs)
Description: Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
Study: NCT05033067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3BC
Description: The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
Study: NCT05198830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and FDG-PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT and FDG-PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo thoracic radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo thoracic radiation
Study: NCT06127667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: use of single bout of aerobic exercise
Study: NCT04039672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: 5mm skin metastasis or primary melanoma biopsy
Study: NCT06079398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg Navepegritide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Navepegritide
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
Study: NCT06319170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Extended Release
Description: Powder and vehicle for injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Extended Release
Description: Powder and vehicle for injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Extended Release
Description: Powder and vehicle for injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: IntraMuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: IntraMuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: IntraMuscular Injection
Study: NCT06528093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765883
Description: BI 765883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765883
Description: BI 765883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765883
Description: BI 765883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel
Study: NCT05724433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual HF Care
Description: Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine HF Care
Description: Care as determined by the treating physician
Study: NCT05091424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive daily oral venetoclax
Study: NCT06534099

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Wuqinxi exercise regimen was conducted under the guidance of a professional Wuqinxi instructor, where the experimental group practiced the five animal forms of the exercise, which include the Tiger, Deer, Bear, Ape, and Bird forms. The exercise period was 24 weeks, with the first 4 weeks designated as the learning phase and weeks 5 to 24 as the consolidation and reinforcement phase. The frequency of exercise was three times per week, with each session lasting 70 minutes, including 10 minutes for warm-up and relaxation activities.
Study: NCT05987813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS Unit
Description: Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS Unit
Description: Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
Study: NCT06328036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical resection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV
Study: NCT04966247

Intervention type: OTHER
Intervention: Microdialysis
Description: Monitoring real-time cerebral biomarkers using microdialysis method
Study: NCT06328036

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tiragolumab
Description: Given IV
Study: NCT05214222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib/Penpulimab/Chemotherapy
Description: Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab/Chemotherapy
Description: Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks Post-progression genetic testing, continued treatment: Anlotinib,Penpulimab Anlotinib: Once daily, one capsule per time (10mg for weight \<60KG, 12mg for weight ≥60KG), administered from day 1 to day 14 of each cycle. Two consecutive weeks of treatment followed by one week off, 3 weeks per treatment cycle.~Penpulimab: 200mg, administered on day 1 of each cycle, every 3 weeks.
Study: NCT04878094

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravenous Indocyanine Green/ICG injection
Description: Intravenous Indocyanine Green/ICG injection will be administered for visualization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PINPOINT endoscopic fluorescence imaging system
Description: After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Standard technique and assessment of anastomosis without the use of NIR angiography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Standard technique and assessment of anastomosis without the use of NIR angiography
Study: NCT05256173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin Tablets
Description: Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactasin Tablets
Description: The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous vagus nerve stimulation
Description: In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
Study: NCT06427226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.
Study: NCT04808323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Dose of Radiation before Dose Escalation
Description: 50 Gy over 25 frac.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Dose of Radiation before Dose Escalation
Description: 50 Gy over 25 frac.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Dose of Radiation before Dose Escalation
Description: 50 Gy over 25 frac.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort A: Dose Escalation Radiation
Description: Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
Study: NCT05973357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-crestal implant
Description: Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Equi-crestal implant
Description: Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
Study: NCT05043298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 360 Injection
Description: IBI 360 dose level of escalation IV Q3W Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 360 Injection Sintilimab
Description: IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
Study: NCT04866173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dog
Description: Subjection to standardised stress situations in the presence of a dog and a person

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Dog
Description: Subjection to standardised stress situations in the presence of a person